ZIOPHARM Announces Positive Interim Results in Patients With Advanced Melanoma From Ongoing Phase 1/2 Study of Ad-RTS-IL-12

ZIOPHARM Oncology (Nasdaq: ZIOP ) today announced positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma. The results from this multicenter study were presented at Melanoma Bridge